Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.7.2845

IL-35 Over-expression is Associated with Genesis of Gastric Cancer  

Fan, Yong-Gang (Departments of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology)
Zhai, Jing-Ming (Departments of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology)
Wang, Wei (Departments of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology)
Feng, Bing (Departments of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology)
Yao, Guo-Liang (Departments of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology)
An, Yan-Hui (Departments of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology)
Zeng, Chao (Department of Pathology, Guangdong Medical College)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.7, 2015 , pp. 2845-2849 More about this Journal
Abstract
Overexpression of interleukin (IL)-35 has been found in a variety of malignancies, but the expression status in gastric cancer has yet to be elucidated clearly. In the present study, positive expression of EBI3 and p35 was 63.3% and 70.0% of cases, respectively. EBI3 expression was strongly related with larger tumor size and invasion depth (P<0.05). Similarly, expression of p35 was also correlated with larger tumor size (P<0.05). These results indicate that IL-35 might be involved in growth of gastric cancer. Interestingly, EBI3 and p35 expressions were positive correlated with Ki-67 expression. Moreover, EBI3 immunoreactivity was associated with Bcl-2 staining. Our data suggest IL-35 is correlated with genesis of gastric cancer by regulating growth and apoptosis.
Keywords
IL-35; gastric cancer; Ki-67; Bcl-2;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Collison LW, Workman CJ, Kuo TT, et al (2007). The inhibitory cytokine IL- 35 contributes to regulatory T- cell function. Nature, 450, 566-9.   DOI
2 Collison LW, Chaturvedi V, Henderson AL, et al (2010). IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol, 11, 1093-101.   DOI
3 Devergne O, Birkenbach M, Kieff E (1997). Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci USA, 94, 12041-6.   DOI
4 Huang CH, Loo EX, Kuo IC, et al (2011). Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. J Immunol, 187, 462-71.   DOI
5 Kochetkova I, Golden S, Holderness K, et al (2010). IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. Immunol, 184, 7144-53.   DOI
6 Larousserie F, Bardel E, Pflanz S, et al (2005). Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am J Pathol, 166, 1217-28.   DOI
7 Li X, Mai J, Virtue A, et al (2012). IL-35 is a novel responsive anti-inflammatory cytokine--a new system of categorizing anti-inflammatory cytokines. PLoS One, 7, 33628.   DOI
8 Long J, Zhang X, Wen M, et al (2013). IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochem Biophys Res Commun, 430, 364-9.   DOI
9 Niedobitek G, Pazolt D, Teichmann M, et al (2002). Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. J Pathol, 198, 310-6.   DOI
10 Niedbala W, Wei XQ, Cai B, et al (2007). IL-35 is a novel cytokine with therapeutic effects against collagen- induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol, 37, 3021-9.   DOI
11 Nishino R, Takano A, Oshita H, et al (2011). Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res, 17, 6272-86.   DOI
12 Pflanz S, Timans JC, Cheung J, et al (2002). IL- 27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4 (+) T cells. Immunity, 16, 779-90.   DOI
13 Poleganov MA, Bachmann M, Pfeilschifter J, et al (2008). Genome-wide analysis displays marked induction of EBI3/IL-27B in IL-18-activated AML-derived KG1 cells: critical role of two kappaB binding sites in the human EBI3 promotor. Mol Immunol, 45, 2869-80.   DOI
14 Schrader JW (2002). Interleukin is as interleukin does. Trends Immunol, 23, 573-4.   DOI
15 Seyerl M, Kirchberger S, Majdic O, et al (2010). Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. Eur J Immunol, 40, 321-9.   DOI
16 Wang Z, Liu JQ, Liu Z, et al (2013). Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol, 190, 2415-23.   DOI
17 Whitehead GS, Wilson RH, Nakano K, et al (2012). IL-35 production by inducible costimulator (ICOS)- positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J Allergy Clin Immunol, 129, 207-15.   DOI
18 Zeng JC1, Zhang Z, Li TY, et al (2013). Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol, 6, 1806-16.